Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-10-18
2005-10-18
Weber, Jon (Department: 1653)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069100, C435S006120, C435S320100, C435S252300, C435S180000, C435S366000, C435S395000, C435S325000, C424S192100, C536S023100, C530S350000
Reexamination Certificate
active
06955898
ABSTRACT:
The present invention provides new compositions and methods to induce therapeutic angiogenesis locally utilizing a collagen binding domain to target an angiogenesis modulating agents. Fusion polypeptides containing a collagen binding domain linked to an angiogenesis modulating agent are provided, as are nucleic acid sequences encoding the fusion polypeptides. Also included are methods for locally altering circulation by administering a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or by administering a nucleic acid sequences encoding the fusion polypeptide. Tissue grafts in which isolated tissue is treated with a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or with a nucleic acid sequences encoding the fusion polypeptide are also provided, as are methods of making the grafts.
REFERENCES:
patent: 5800811 (1998-09-01), Hall et al.
patent: 6004798 (1999-12-01), Anderson et al.
patent: WO 96/39430 (1996-12-01), None
patent: WO 98/44938 (1998-10-01), None
patent: WO 98/51700 (1998-11-01), None
Nishi, N. et al., “Collagen-binding growth factors: Production and characterization of functional fusion proteins having a collagen-binding domain”, Jun. 1998, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 7018-7023.
Gordon, E.M. et al., “Capture and expansion of bone marrow-derived mesenchymal progenitor cells with a transforming growth factor-β1-von Willebrand's factor fusion protein for retrovirus-mediated delivery of coagulation factor IX”, Jul. 20, 1997, Human Gene Therapy, vol. 8, pp. 1385-1394.
Sadler, J.E. et al., “Cloning and characterization of two cDNAs coding for human von Willebrand factor”, Oct. 1985, Natl. Acad. Sci. USA, vol. 82, pp. 6394-6398.
Magovern et al., “Regional Angiogenesis Induced in Nonischemic Tissue by an Adenoviral Vector Expressing Vascular Endothelial Growth Factor,”Human Gene Therapy, 8:215-227 (Jan. 20, 1997).
Klagsbrun et al., Annual Review of Physiology, vol. 53, pp. 217-239, 1991.
Takagi et al., Biochemistry, vol. 31, pp. 8530-8534, 1992.
Anderson W. French
Gordon Erlinda M.
Hall Frederick L.
Starnes Vaughn A.
Fish & Richardson P.C.
Robinson Hope A.
University of Southern California
Weber Jon
LandOfFree
Targeting pharmaceutical agents to injured tissues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeting pharmaceutical agents to injured tissues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeting pharmaceutical agents to injured tissues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3487383